ClearPoint Neuro, Inc.

NASDAQ:CLPT

Medical - Devices

Healthcare
$7.71 +5.30%

+$0.89 today

Market cap
$247.14M
Beta
1.31
P/E (TTM)
-18.0
EPS (TTM)
-$0.98
52W Low $8.27High $30.10

Volume 0.64M

Average 0.67M

CLPT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

ClearPoint Neuro, Inc.NASDAQ: CLPT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $4.52M rose 33.8% year over year, ahead of the +14.4% change in trailing-twelve-month research & development. Sequentially, it rose 39.7% from the prior quarter. Over 3 fiscal years it compounded at +8.5% a year.

Context

  • Research & development amounted to 37.6% of revenue in FY2025, down 1.9 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +33.8% holds above the trailing-twelve-month pace of +14.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.52M+39.7% QoQ
Last fiscal yearDec 2025
$13.9M+12.1% YoY
LTMMar 2026
$15.04M+14.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.8%——
1 year+12.1%——
3-year CAGR+8.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
13.9M USD
Year-over-year change
+12.1%
4-year CAGR
+10.6%

Research & Development vs competitors

How CLPT compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.4% is the 2nd highest of 10, against a peer median of -6.9%.
  • Research & development amounts to 37.0% of revenue for CLPT, versus a peer median of 9.4%.
CLPT Competitors
Research & Development for CLPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CMPSCOMPASS Pathways plcLTM Mar 2026$110.07M USD-12.0%+22.1%—
VREXVarex Imaging CorporationLTM Apr 2026$89.5M USD+0.1%+5.8%10.4%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$67.09M USD+78.1%-27.8%28.9%
OFIXOrthofix Medical Inc.LTM Mar 2026$61.4M USD-16.9%+5.2%7.4%
CTKBCytek Biosciences, Inc.LTM Mar 2026$36.35M USD-7.6%+1.5%17.8%
AVNSAvanos Medical, Inc.LTM Mar 2026$22.9M USD-6.9%-8.9%3.2%
LABStandard BioTools Inc.LTM Mar 2026$22.48M USD-43.6%-11.4%26.1%
SIBNSI-BONE, Inc.LTM Mar 2026$17.11M USD+2.1%+8.6%8.3%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$15.04M USD+14.4%+8.5%37.0%
SNDLSNDL Inc.LTM Mar 2026CA$393K CAD-3.9%-41.5%0.0%
Peer median (excluding CLPT) —-6.9%+1.5%9.4%

Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue16.3M20.55M23.96M31.39M36.97M
Cost of Revenue5.18M7.02M10.34M12.27M14.28M
Gross Profit11.12M13.53M13.61M19.12M22.69M
Gross Margin68.2%65.8%56.8%60.9%61.4%
Research & Development9.28M10.89M11.71M12.39M13.9M
Selling, General & Admin15.22M18.97M24.35M26.48M32.96M
Operating Expenses24.5M29.86M36.06M38.87M46.86M
Depreciation & Amortization692K777K1.46M1.9M2.24M
EBITDA(12.75M)(15.58M)(20.63M)(17.01M)(20.86M)
EBITDA Margin-78.2%-75.8%-86.1%-54.2%-56.4%
Operating Income(13.37M)(16.33M)(22.45M)(19.75M)(24.16M)
Operating Margin-82.1%-79.5%-93.7%-62.9%-65.4%
Interest Income00386K872K1.21M
Interest Expense973K81K002.39M
Other Income / Expenses(1.04M)(103K)357K832K(1.32M)
Income Before Tax(14.41M)(16.44M)(22.09M)(18.91M)(25.49M)
Pre-Tax Margin-88.4%-80.0%-92.2%-60.3%-68.9%
Income Tax Expense000055K
Net Income(14.41M)(16.44M)(22.09M)(18.91M)(25.54M)
Net Margin-88.4%-80.0%-92.2%-60.3%-69.1%
EPS (Basic)(0.69)(0.68)(0.90)(0.70)(0.90)
EPS (Diluted)(0.69)(0.68)(0.90)(0.70)(0.90)
Weighted Avg Shares20.73M24.18M24.61M27.03M28.32M
Weighted Avg Shares (Diluted)20.73M24.18M24.61M27.03M28.32M

ClearPoint Neuro, Inc.

NASDAQ:CLPT

Intrinsic Alpha fair value

Locked

Current Price

$7.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.